Mimix™ Non-Small Cell Lung Cancer Panel, ctDNA Reference Standard
Improve your MRD assay validations using our new Non-Small Cell Lung Cancer ctDNA Reference Standard. It is a well characterized, cell line-derived control material manufactured under ISO 9001:2015 and ISO 13485:2016 that contains 22 clinically relevant variants across 7 genes.
Clearance sale: Discounted pricing on selected cfDNA inventory. Limited availability.*
*This pricing promotion is only valid on selected products and while stocks last. Not valid in Italy and China. The promotion cannot be combined with any other promotions, discounts, or offers. Conditions of the promotions may change, and Revvity may void, change, cancel, suspend, or amend this promotion without notice.
According to the global cancer statistics GLOBOCAN (Sung et al., 2020), lung cancers are the leading cause of cancer mortality worldwide. With several ctDNA based early diagnostic and prognostic tests being developed for targeted therapies, the need for a preferred reference standard is paramount. Not all lung cancers share the same gene mutations hence, this panel will be supporting DNA mutations in Non-Small Cell Lung Cancer (NSCLC) which accounts for ~85% of all the lung cancer cases. This panel covers the significant DNA driver mutations responsible for NSCLC in EGFR, KRAS, BRAF and rare mutations in genes like MET, ERBB, PIK3CA, NRAS (see table below for mutation information). To aid in validations of liquid biopsy based companion diagnostic (CDx) tests, this panel is made in ctDNA format. With allelic frequencies as low as 0.30%, this panel can be used in validating assays designed for MRD testing.
Unlike synthetic reference materials, this panel is made with a unique blend of engineered cell lines mimicking patient samples, retaining the complexity of a biological sample. As always, all our reference standards are manufactured under ISO 9001:2015 and ISO 13485:2016.
Technical data
Format: ctDNA
Genes covered: EGFR, KRAS, BRAF, MET, ERBB2, PIK3CA, NRAS
Allelic frequencies: 0.30% - 1.20%
Buffer: Tris-EDTA (10mM Tris-HCl, 1mM EDTA), pH 8.0
Product information
Fragment size: 160 bp
Unit size: 350 ng per vial
Concentration: 20 ng/µL
Verified mutations:
| Gene | DNA sequence change | Amino acid change | Expected allelic frequency (%) |
|---|---|---|---|
| BRAF | c.1799T>A | p.V600E | 1.20 |
| EGFR | c.2156G>C | p.G719A | 0.50 |
| EGFR | c.2303G>T | p.S768I | 0.80 |
| EGFR | c.2582T>A | p.L861Q | 0.80 |
| EGFR | c.2573T>G | p.L858R | 0.80 |
| EGFR | c.2235_2249del | p.E746_A750del | 0.80 |
| EGFR | c.2236_2250del | p.E746_A750del | 0.80 |
| EGFR | c.2240_2257del | p.L747_P753delinsS | 1.00 |
| EGFR | c.2369C>T | p.T790M | 0.80 |
| ERBB2 | N/A | Amplification | 6 copies |
| ERBB2 | c.2313_2324dup | p.Y772_A775dup | 0.30 |
| ERBB2 | c.2331_2339dup | p.G778_P780dup | 0.30 |
| KRAS | c.34G>T | p.G12C | 1.00 |
| KRAS | c.35G>T | p.G12V | 0.50 |
| KRAS | c.35G>A | p.G12D | 1.00 |
| MET | N/A | Amplification | 4 copies |
| MET | c.3082+1G>T | Unknown (Exon 14 skipping) | 0.80 |
| NRAS | c.181C>A | p.Q61K | 0.50 |
| NRAS | c.182A>T | p.Q61L | 0.50 |
| NRAS | c.182A>G | p.Q61R | 0.50 |
| PIK3CA | c.1624G>A | p.E542K | 1.00 |
| PIK3CA | c.3140A>G | p.H1047R | 0.8 |
General information
Storage: 4°C
Expiration: See all product shelf life information
Intended use: For assay developers, molecular diagnostic labs (Research use only)
Quality control
Fragmentation size: D1000 DNA ScreenTape assay
Allelic frequency: Droplet Digital™ PCR
Quantification: Qubit® dsDNA BR assay (Invitrogen)
Intended use: For assay developers and molecular diagnostic labs for routine performance monitoring of molecular biology assays. Research use only. Not for diagnostic procedures.
References
- Kris MG, Camidge DR, Giaccone G, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol. 2015;26(7):1421-1427. doi:10.1093/annonc/mdv186
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
We accept orders using the following methods.
Online
Our online catalog and ordering system can be used to search our full menu of available Reference Standards. Select your desired reference standards and add them to the shopping basket. Your order can be submitted instantly using credit card, telephone ordering or a purchase order number as the preferred payment method.
Offline
If you prefer to send us orders outside our online ordering system, please see the Contact Us page for telephone, fax, and email details in order to place an order. We recommend that you use our online system to identify the products you require and their respective “HD” product codes.
To order offline we will require the following information:
- Product code(s) of the item(s) you wish to order (e.g. "HD123")
- Your name, email address, title and organization
- Shipping address and billing address with contact names
- Purchase Order number if you have one
- Telephone number
- VAT Number (European Countries only)
If you’re having trouble ordering or finding what you’re looking for, or if you require something we don’t yet offer, please contact us.
Reference Standards
-
At what temperature do you ship reference standards?
-
How are Horizon cfDNA and ctDNA Reference Standards different from other circulating tumor DNA controls?
-
How are Horizon cfDNA and ctDNA Reference Standards fragmented?
-
How do you manufacture your Horizon Reference Standards?
-
Is it possible to order custom versions of Horizon Reference Standard?
-
Is there a wild-type control in the same background as NSCLC ctDNA Panel Reference Standard (HD844)?
-
What are cfDNA Reference Standards?
-
What is MRD?
-
What is the difference between ctDNA and cfDNA?
-
Which Droplet Digital PCR (ddPCR) system is used for variant detection at Horizon?
Related Products
Special Discount Pricing: The Non-Small Cell Lung Cancer ctDNA Panel Reference Standard negative control is well characterized, cell line-derived control material manufactured under ISO 9001:2015 and ISO 13485:2016 that is tested negative for 22 variants across 7 genes clinically relevant to NSCLCs.